




About us

Fresenius Medical Care is the world’s largest provider of products and services for individuals with renal diseases of which around 2.8 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,418 dialysis clinics, Fresenius Medical Care provides dialysis treatment for more than 294,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding in the range of additional medical services in the field of care coordination.

Key figures – full year 2015

Net revenue	\$	16,738 M	+6%/+11%cc
Operating income (EBIT)	\$	2,327 M	+3%
Operating income (EBIT) excluding special items ¹	\$	2,388 M	+5%
Net income ²	\$	1,029 M	-2%
Net income excluding special items ^{1,2}		1,082 M	+2%
Basic earnings per share	\$	3.38	-2%
Net cash provided by operating activities	\$	1,960 M	
Free cash flow	\$	1,025 M	
Free cash flow after investing activities	\$	959 M	
Employees		104,033	+4%


Revenue full year 2015 per region (in \$million)




Patients, treatments, clinics – full year 2015

	Patients	Treatments (in M)	Clinics
North America	182,852	27.7	2,210
EMEA	54,857	8.2	659
Asia-Pacific	26,472	3.8	320
Latin America	30,200	4.9	229

Basic earnings & dividend per share



Balance sheet (in \$million)



Strategy

Our strategy in the coming years will pursue the following four strategic objectives:

- Growing continuously and expanding our global presence
- Tapping into new business areas
- Enhancing products and treatments
- Expanding operational excellence and flexibility

Goals for 2016

Growth in revenue	~7-10%
Net income ²	~15-20%
Leverage ratio (Debt/EBITDA)	<3.0
Capital expenditures	\$1.0 - \$1.1 BN
Acquisitions	~\$750 M

¹Excluding special items: divestiture of dialysis business in Venezuela, sale of the European marketing rights to Vifor and settlement costs for an agreement principle for the Granuflo® case in 2015 as well as closing of manufacturing plants in 2014.

²attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

³Subject to approval by the Annual General Meeting on May 12, 2016.



History

- September 30, 1996: Foundation of the company
- October 1, 1996: First listing of the shares on the Frankfurt Stock Exchange
- October 2, 1996: First listing of the shares on the New York Stock Exchange
- As of September 20, 1999: Inclusion in the DAX (Deutscher Aktienindex)

Share price - last 12 months (in €)



Basic share data


Ticker Symbols:

Frankfurt Stock Exchange	FME
New York Stock Exchange (NYSE)	FMS
Reuters: XETRA / ADR NYSE:	FMEG.DE/FMS.N
Bloomberg: XETRA / ADR NYSE:	FME GY / FMS US

Security Identification numbers:

WKN	578 580
ISIN	DE 0005785802
CUSIP No. (NYSE)	358029106

Geographical distribution of identified shares



Share data

Number of shares outstanding	306,314,071
<i>Fresenius SE & Co. KGaA</i>	30.91%
BlackRock ⁴	>5%
Free float	~64%
Market capitalization	\$22.8 M

Ratings

Standard & Poor's	BBB- / stable outlook
Moody's	Ba1 / stable outlook
Fitch	BB+ / stable outlook

Management Board

- Rice Powell (Chairman)
- Michael Brosnan (Finance)
- Roberto Fusté (Asia-Pacific)⁵
- Ronald Kuerbitz (North America)
- Dr. Olaf Schermeier (Research & Development)
- Kent Wanzek (Production)
- Dominik Wehner (Europe, Middle East, Africa)

Supervisory Board

- Dr. Gerd Krick (Chairman)
- Dr. Dieter Schenk (Vice Chairman)
- Dr. Walter L. Weisman
- Rolf A. Classon
- William P. Johnston
- Prof. Dr. Bernd Fahrholz

Financial calendar

Report on 1 st quarter 2016:	May 3, 2016
Annual General Meeting 2016:	May 12, 2016
Dividend payment ⁶ :	May 13, 2016
Report on 2 nd quarter 2016:	August 2, 2016
Report on 3 rd quarter 2016:	October 27, 2016

Please note that these dates might be subject to changes.

⁴as of February 19, 2016.

⁵Effective April 1, 2016 Roberto Fusté will be succeeded by Harry De Wit.

⁶Subject to approval by the Annual General Meeting on May 12, 2016.

Contacts

Fresenius Medical Care AG & Co. KGaA
Investor Relations & Corporate Communications
Else-Kröner-Str. 1, 61352 Bad Homburg
Email: ir@fmc-ag.com

Oliver Maier

Senior Vice President & Head of IR

P: +49(0)6172-609-2525 F: +49(0)6172-609-2301